Difference between revisions of "Part:BBa K2933204"
(→Molecular cloning) |
(→Usage and Biology) |
||
(2 intermediate revisions by the same user not shown) | |||
Line 17: | Line 17: | ||
<partinfo>BBa_K2933204 parameters</partinfo> | <partinfo>BBa_K2933204 parameters</partinfo> | ||
<!-- --> | <!-- --> | ||
− | ==Usage and Biology | + | ==Usage and Biology== |
− | This composite part is made up with seven basic parts, the His tag, T7 promoter, RBS and our target protein SPG-1. It encodes a protein which is SPG-1 fused with His tag. The fusion protein is about 30.2 kD. In order to gain the highly purified target protein, we add His tag in N-terminal of SPG-1. It is convenient for us to purify our target protein.<br> | + | This composite part is made up with seven basic parts, the His tag, T7 promoter, RBS ,Linker h ,Linker f,T7 terminator and our target protein SPG-1. It encodes a protein which is SPG-1 fused with His tag. Linker h is from the vector pET-28a, which connects the RBS to His tag sequence.Linker f from vector pGEX-6p-1, contains the thrombin restriction site and T7 tag.The fusion protein is about 30.2 kD. In order to gain the highly purified target protein, we add His tag in N-terminal of SPG-1. It is convenient for us to purify our target protein.<br> |
===Molecular cloning=== | ===Molecular cloning=== | ||
First, we used the vector pGEX-28a to construct our expression plasmid. And then we converted the plasmid constructed to ''E. coli'' DH5α to expand the plasmid largely.<br> | First, we used the vector pGEX-28a to construct our expression plasmid. And then we converted the plasmid constructed to ''E. coli'' DH5α to expand the plasmid largely.<br> | ||
Line 30: | Line 30: | ||
'''Pre-expression:'''<br> | '''Pre-expression:'''<br> | ||
The bacteria were cultured in 5mL LB liquid medium with ampicillin(100 μg/mL final concentration) in 37℃ overnight.<br> | The bacteria were cultured in 5mL LB liquid medium with ampicillin(100 μg/mL final concentration) in 37℃ overnight.<br> | ||
+ | ===References=== | ||
+ | [1]The Soil Microbiota Harbors a Diversity of Carbapenem-Hydrolyzing β-Lactamases of Potential Clinical Relevance. Gudeta DD, Bortolaia V, Amos G, Wellington EM, Brandt KK, Poirel L, Nielsen JB, Westh H, Guardabassi L. Antimicrob Agents Chemother. 2015 Oct 19;60(1):151-60. |
Latest revision as of 14:00, 23 September 2019
T7 promoter+RBS b+Linker h+His+Linker f+SPG-1+T7 terminator
This part consists of T7 promoter, RBS and protein coding sequence(His+Linker f+SPG-1),and the biological module can be built into E.coli for protein expression
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal XbaI site found at 47
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 169
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal XbaI site found at 47
- 25INCOMPATIBLE WITH RFC[25]Illegal XbaI site found at 47
- 1000COMPATIBLE WITH RFC[1000]
Usage and Biology
This composite part is made up with seven basic parts, the His tag, T7 promoter, RBS ,Linker h ,Linker f,T7 terminator and our target protein SPG-1. It encodes a protein which is SPG-1 fused with His tag. Linker h is from the vector pET-28a, which connects the RBS to His tag sequence.Linker f from vector pGEX-6p-1, contains the thrombin restriction site and T7 tag.The fusion protein is about 30.2 kD. In order to gain the highly purified target protein, we add His tag in N-terminal of SPG-1. It is convenient for us to purify our target protein.
Molecular cloning
First, we used the vector pGEX-28a to construct our expression plasmid. And then we converted the plasmid constructed to E. coli DH5α to expand the plasmid largely.
Figure 1. The PCR result of SPG.
After verification, it was determined that the construction is successful. We converted the plasmid to E. coli BL21(DE3) for expression and purification.
Expression and purification
Pre-expression:
The bacteria were cultured in 5mL LB liquid medium with ampicillin(100 μg/mL final concentration) in 37℃ overnight.
References
[1]The Soil Microbiota Harbors a Diversity of Carbapenem-Hydrolyzing β-Lactamases of Potential Clinical Relevance. Gudeta DD, Bortolaia V, Amos G, Wellington EM, Brandt KK, Poirel L, Nielsen JB, Westh H, Guardabassi L. Antimicrob Agents Chemother. 2015 Oct 19;60(1):151-60.